Investigational smallpox vaccine, IMVAMUNE, has successful Phase 3 clinical trial
by Press Release from Outbreak News Today on (#3FEZB)
Officials from Bavarian Nordic yesterday announced the results of a successful Phase 3 clinical trial led by USAMRIID that demonstrated the safety and efficacy of the company's investigational, non-replicating smallpox vaccine, IMVAMUNE(R). The product is being developed as an alternative to the current U.S. licensed replicating smallpox vaccine, ACAM2000(R), which cannot be used by certain ["]
The post Investigational smallpox vaccine, IMVAMUNE, has successful Phase 3 clinical trial appeared first on Outbreak News Today.